Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 10/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346457 | 0.88 | FGFR3 (0.38) | FGFR3ADORA2AADORA1CYSLTR1KDM4E | |
| SCHEMBL3352671 | 0.85 | FGFR3 (0.44) | FGFR3ADORA2AADORA1 | |
| SCHEMBL1126690 | 0.83 | FGFR3 (0.51) | FGFR3KDM4EALDH1A1 | |
| SCHEMBL1126337 | 0.83 | FGFR3 (0.42) | FGFR3ADORA2AADORA1HDAC1 | |
| SCHEMBL1126454 | 0.82 | FGFR3 (0.59) | FGFR3KDM4EHPGDS | |
| SCHEMBL1127069 | 0.78 | FGFR3 (0.49) | FGFR3HPGDS | |
| SCHEMBL3348914 | 0.77 | FGFR3 (0.42) | FGFR3KDM4EALDH1A1HPGDS | |
| SCHEMBL17023109 | 0.73 | HRH3 (0.41) | FGFR3KDM4EALDH1A1 | |
| SCHEMBL1126916 | 0.72 | FGFR3 (0.47) | FGFR3KDM4E | |
| SCHEMBL1126038 | 0.72 | FGFR3 (0.51) | FGFR3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885ADORA2A 2998/4885ADORA1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.